Chemotherapy Induced Peripheral Neuropathy (CIPN) and Lymphoma Longitudinal Follow-up and Prognostic Factors

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-01-10

Study Completion Date

2025-03-11

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Vincristine-induced peripheral neuropathy, which is commonly a sensorimotor neuropathy, remains a major complication of lymphoma patients treated with R-CHOP. The investigators propose a clinical, electrophysiological and biological follow up of patients treated by vincristine for lymphoma to determine the factors implied in VIPN occurrence.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Capsaicin 179 mg Patch Versus Oral Duloxetine in Patients With Chemotherapy-induced Peripheral Neuropathy

NCT05840562

Chemotherapy-induced Peripheral Neuropathy

RECRUITING PHASE3

Understanding and Preventing Cortical Mechanisms of Chemotherapy-induced Peripheral Neuropathy

NCT06389721

Chemotherapy-induced Peripheral Neuropathy

RECRUITING

Chronic Neuropathy Following Chemotherapy

NCT02654691

Peripheral Nervous System Diseases Chronic Pain

COMPLETED

Topical Menthol for the Treatment of Chemotherapy Induced Peripheral Neuropathy

NCT01855607

Breast Cancer Colon Cancer Neuropathy

TERMINATED PHASE2

The Role of TRP Channels in CIPN

NCT04415892

Chemotherapy-induced Peripheral Neuropathy

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients with lymphoma will be evaluated before chemotherapy (T1), after 4 cycles (T2), at the end of the chemotherapy treatment (If more than 4 cycles) (T3) and 6 month after the end of chemotherapy (T4).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lymphoma Peripheral Neuropathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Clinical scales of CIPN

Patients with lymphoma will be evaluated before chemotherapy (T1), after 4 cycles (T2), at the end of the chemotherapy treatment (If more than 4 cycles) (T3) and 6 month after the end of chemotherapy (T4).

Group Type OTHER

Clinical scales of CIPN

Intervention Type OTHER

Patients with lymphoma will be evaluated before chemotherapy (T1), after 4 cycles (T2), at the end of the chemotherapy treatment (If more than 4 cycles) (T3) and 6 month after the end of chemotherapy (T4).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Clinical scales of CIPN

Patients with lymphoma will be evaluated before chemotherapy (T1), after 4 cycles (T2), at the end of the chemotherapy treatment (If more than 4 cycles) (T3) and 6 month after the end of chemotherapy (T4).

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of indolent or aggressive B/T NHL confirmed by biopsy and requiring chemotherapy after PCR decision including vincristine, RCHOP/CHOP protocol or CHOEP
* Accept to participate in the study
* Age \> 18 year
* Able and willing to provide informed consent
* Affiliated to a social security system

Exclusion Criteria

* Life-threatening emergency requiring chemotherapy in extreme urgency
* Neuro-meningeal damage at diagnosis
* Protected person (under guardianship or curators)
* Person under court protection
* Pregnant or breastfeeding woman
* Persons deprived of liberty by judicial or administrative decision
* Persons under forced psychiatric care
* Persons admitted to a health or social institution for purposes other than research
* Persons unable to express their consent

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No